Deo M G
Cancer Research Institute, Parel, India.
Vaccine. 1989 Apr;7(2):92-3. doi: 10.1016/0264-410x(89)90041-8.
A vaccine containing ICRC bacilli, which are leprosy-derived cultivable mycobacteria, induces lepromin conversion in LL patients and lepromin-negative persons. 'Up-grading' of lesions and reversal reaction are observed in some vaccinated patients. The bacillus shows antigenic cross-reactivity with Mycobacterium leprae. These observations provided the basis for launching a large-scale field trial of the vaccine in India in February 1987. The objective of the two-arm trial is to assess efficacy of the ICRC vaccine against BCG, which forms the control arm, in lowering the incidence of leprosy in healthy household contacts of leprosy patients. Recently, a very high molecular weight fraction, named PP-I, has been isolated from the sonicate of ICRC bacilli. PP-I, which is a glycolipoprotein, is a strong T-cell immunogen and shows antigenic cross-reactivity with a similar fraction isolated from M. leprae. A 'subunit' vaccine containing the PP-I of ICRC bacilli is currently undergoing phase I and II clinical trials in India.
一种含有国际抗麻风病协会（ICRC）杆菌的疫苗，这些杆菌是源自麻风病的可培养分枝杆菌，可使瘤型麻风（LL）患者和麻风菌素阴性者发生麻风菌素转化。在一些接种疫苗的患者中观察到皮损“升级”和逆转反应。该杆菌与麻风分枝杆菌存在抗原交叉反应。这些观察结果为1987年2月在印度开展该疫苗的大规模现场试验奠定了基础。双臂试验的目的是评估ICRC疫苗相对于作为对照臂的卡介苗（BCG）在降低麻风病患者健康家庭接触者中麻风病发病率方面的疗效。最近，从ICRC杆菌的超声裂解物中分离出一种非常高分子量的组分，命名为PP-I。PP-I是一种糖脂蛋白，是一种强大的T细胞免疫原，并且与从麻风分枝杆菌中分离出的类似组分存在抗原交叉反应。一种含有ICRC杆菌PP-I的“亚单位”疫苗目前正在印度进行I期和II期临床试验。
